Dabomb Protein (6578) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dabomb Protein (6578) has a cash flow conversion efficiency ratio of 0.000x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-354.00K ≈ $-11.15K USD) by net assets (NT$989.28 Million ≈ $31.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 6578 stock market capitalisation for the company's overall valuation and market capitalisation.
Dabomb Protein - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Dabomb Protein's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dabomb Protein Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dabomb Protein ranked by their cash flow conversion efficiency. Explore 6578 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LAVA THERAP. B.V. EO-12
F:4PKB
|
N/A |
|
Abnova Taiwan Corp
TW:4133
|
0.010x |
|
AbL Diagnostics SA
PA:ABLD
|
0.063x |
|
Derimod Konfeksiyon Ayakkabi Deri Sanayi ve Ticaret AS
IS:DERIM
|
1.189x |
|
Space Com
TA:SCC
|
-0.893x |
|
Orient Paper & Industries Limited
NSE:ORIENTPPR
|
-0.008x |
|
Casing Macron Technology Co Ltd
TWO:3325
|
0.008x |
|
Karyopharm Therapeutics Inc
NASDAQ:KPTI
|
0.076x |
Annual Cash Flow Conversion Efficiency for Dabomb Protein (2015–2025)
The table below shows the annual cash flow conversion efficiency of Dabomb Protein from 2015 to 2025. View today's stock price for Dabomb Protein for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$989.28 Million ≈ $31.17 Million |
NT$16.65 Million ≈ $524.44K |
0.017x | -61.46% |
| 2024-12-31 | NT$1.09 Billion ≈ $34.32 Million |
NT$47.55 Million ≈ $1.50 Million |
0.044x | +542.86% |
| 2023-12-31 | NT$958.06 Million ≈ $30.18 Million |
NT$6.51 Million ≈ $204.97K |
0.007x | -74.94% |
| 2022-12-31 | NT$727.20 Million ≈ $22.91 Million |
NT$19.71 Million ≈ $620.85K |
0.027x | +141.29% |
| 2021-12-31 | NT$674.24 Million ≈ $21.24 Million |
NT$-44.25 Million ≈ $-1.39 Million |
-0.066x | -442.83% |
| 2020-12-31 | NT$700.51 Million ≈ $22.07 Million |
NT$13.41 Million ≈ $422.52K |
0.019x | -59.80% |
| 2019-12-31 | NT$698.39 Million ≈ $22.00 Million |
NT$33.26 Million ≈ $1.05 Million |
0.048x | +53.30% |
| 2018-12-31 | NT$710.52 Million ≈ $22.39 Million |
NT$22.07 Million ≈ $695.42K |
0.031x | -55.90% |
| 2017-12-31 | NT$622.77 Million ≈ $19.62 Million |
NT$43.87 Million ≈ $1.38 Million |
0.070x | -26.73% |
| 2016-12-31 | NT$619.77 Million ≈ $19.53 Million |
NT$59.58 Million ≈ $1.88 Million |
0.096x | -59.24% |
| 2015-12-31 | NT$592.64 Million ≈ $18.67 Million |
NT$139.78 Million ≈ $4.40 Million |
0.236x | -- |
About Dabomb Protein
DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its n… Read more